drugset / Trial / NCT06726096
Phase III Trial of VDJ001 In Patients With Moderate-to-severe Active Rheumatoid Arthritis
RandomizedParallel-groupDouble-blindTreatment
Summary
A multicenter, randomized, double-blind, placebo-controlled, and active drug-controlled Phase III pivotal clinical trial of recombinant humanized anti-interleukin-6 receptor monoclonal antibody injection (VDJ001) for the treatment of moderate-to-severe active rheumatoid arthritis with poor response to methotrexate
Timeline
- Start
- 2025-04-09
- Primary completion
- 2026-04-20
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | — |
| Subject | VDJ001 | Monoclonal antibody | 6 mg/kg | — |